Stock in Threshold Pharmaceuticals Inc. surged more than 131 percent on news that it signed a deal with Merck KGaA valued at up to $550 million to develop and commercialize Threshold's cancer candidate, TH-302. Read More
If you were looking for a sign that post-J.P. Morgan optimism and a flurry of drug approvals might blow the biotech initial public offering (IPO) window open again – keep looking. Read More
Resveratrol, a compound found in minuscule doses in foods including red wine and chocolate, is as close to ambrosia – the food of the ancient Greek Gods that gave them eternal youth – as anyone has come. It activates sirtuins and mimics the effects of caloric restriction, which is the only known way to reliably increase lifespan. Read More
Gilead Sciences Inc.'s fourth-quarter earnings fell short of expectations, but the Foster City, Calif.-based firm's stock jumped Friday on promising early data from newly acquired hepatitis C virus (HCV) drug GS-7977. Read More
• Retrosense Therapeutics LLC, of Ann Arbor, Mich., received a grant of $250,000 from the Foundation Fighting Blindness to support development of its investigational gene therapy product based on genes from blue-green algae. The foundation may invest additional funds upon achievement of certain milestones in the research. The company anticipates beginning clinical trials in two to four years. Read More
• Exelixis Inc., of South San Francisco, reported preliminary data from a Phase Ib drug interaction trial of cabozantinib in renal cell carcinoma, showing a high rate of durable tumor response, with a low rate of primary refractoriness to drug therapy, and a long median progression-free survival. Read More
Researchers from the Japanese Osaka University have uncovered an unexpected mechanism by which autoimmune T cells cross the blood-brain barrier in mice with the animal equivalent of multiple sclerosis. Read More
